CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionCurrent ratio is 0.66×, lower than 95% of its Biotechnology peers (median 5.64×)
- FinancialsAltman Z-Score 0.21: distress zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.07BHKD519.16M · vs all stocks (USD)
Revenue (TTM)
1.36BCNY172.95M · vs all stocks (USD)
Profit Margin
-57.95%vs Biotechnology peers
Beta
0.0980xvs all stocks
52-Week Change
-70.55%vs all stocks
Market Capitalization
4.07BHKD519.16M · vs all stocks (USD)
Enterprise Value
4.04BHKD515.30M · vs all stocks (USD)
Forward P/E
1.10xvs Biotechnology peers
Price to Sales (TTM)
1.58xvs Biotechnology peers
Price to Book (MRQ)
0.5750xvs Biotechnology peers
Enterprise to Revenue
2.98xvs Biotechnology peers
Enterprise to EBITDA
-38.84xvs Biotechnology peers
Profit Margin
-57.95%vs Biotechnology peers
Operating Margin
-11.70%vs Biotechnology peers
Return on Assets (TTM)
-1.88%vs Biotechnology peers
Return on Equity (TTM)
-22.72%vs Biotechnology peers
Revenue (TTM)
1.36BCNY172.95M · vs all stocks (USD)
Revenue per Share (TTM)
0.9520CNYUpdated Aug 21, 2026Quarterly Revenue Growth
-12.90%vs Biotechnology peers
Gross Profit (TTM)
884.71MCNY112.79M · vs all stocks (USD)
EBITDA (TTM)
-104.06MCNY-13.27M · vs all stocks (USD)
Net Income (TTM)
-786.09MCNY-100.22M · vs all stocks (USD)
Operating Cash Flow (TTM)
78.52MCNY10.01M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-151.67MCNY-19.34M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00HKDUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
177.32MCNYFY2025 · Dec 31, 2025Revenue
1.17BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
405.47MCNYFY2025 · Dec 31, 2025Gross Profit
760.20MCNYFY2025 · Dec 31, 2025Operating Income
-192.02MCNY-28.56M · vs all stocks (USD)
Pre-tax Income
-766.56MCNYFY2025 · Dec 31, 2025Income Tax Expense
-22.83MCNYFY2025 · Dec 31, 2025Net Income
-743.73MCNYFY2025 · Dec 31, 2025EBIT
-708.71MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-31.63MCNYFY2025 · Dec 31, 2025Research & Development
191.28MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
783.81MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
3.43MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
57.84MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.5500CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.5500CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
1.22BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
1.22BSharesFY2025 · Dec 31, 2025Minority Interests (P&L)
68.27MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-816.41MCNYFY2025 · Dec 31, 2025Free Cash Flow
-930.56MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
342.58MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-766.56MCNYFY2025 · Dec 31, 2025Other Non-cash Items
48.35MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-66.83MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-31.37MCNYFY2025 · Dec 31, 2025Capital Expenditures
-114.15MCNYFY2025 · Dec 31, 2025Net Intangibles (CF)
-124.36MCNYFY2025 · Dec 31, 2025Purchase of Investments
-23.00MCNYFY2025 · Dec 31, 2025Sale of Investments
110.01MCNYFY2025 · Dec 31, 2025Other Investing Activity
39.76MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
12.63MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
1.20BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-1.31BCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-32.64MCNYFY2025 · Dec 31, 2025Shares Outstanding
1.23BSharesUpdated Aug 21, 2026Float Shares
353.90MSharesUpdated Aug 21, 2026% Held by Insiders
29.27%vs all stocks
% Held by Institutions
2.27%vs all stocks
Total Cash (MRQ)
413.86MCNY52.76M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.2900CNYUpdated Aug 21, 2026Total Debt (MRQ)
2.04BCNY260.59M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.5981xvs Biotechnology peers
Current Ratio (MRQ)
0.6610xvs Biotechnology peers
Book Value per Share (MRQ)
2.62CNYUpdated Aug 21, 2026Total Assets
6.54BCNY973.23M · vs all stocks (USD)
Total Current Assets
2.04BCNYFY2025 · Dec 31, 2025Total Liabilities
3.61BCNYFY2025 · Dec 31, 2025Total Non-current Assets
4.50BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
515.02MCNYFY2025 · Dec 31, 2025Total Current Liabilities
3.09BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
342.58MCNYFY2025 · Dec 31, 2025Other Short-term Investments
13.04MCNYFY2025 · Dec 31, 2025Accounts Receivable
1.24BCNYFY2025 · Dec 31, 2025Inventory
347.41MCNYFY2025 · Dec 31, 2025Accounts Payable
79.97MCNYFY2025 · Dec 31, 2025Short-term Debt
1.40BCNYFY2025 · Dec 31, 2025Long-term Debt
356.90MCNYFY2025 · Dec 31, 2025Common Stock (Book)
1.23BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.94BCNY436.69M · vs all stocks (USD)
52-Week Low
1.20HKDUpdated Aug 21, 202652-Week High
5.65HKDUpdated Aug 21, 202652-Week Change
-70.55%vs all stocks
Beta
0.0980xvs all stocks
50-Day MA
1.65HKDUpdated Aug 21, 2026200-Day MA
2.72HKDUpdated Aug 21, 2026Avg 10-Day Volume
125.16KSharesUpdated Aug 21, 2026Avg 30-Day Volume
132.75KSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-0.6400CNYUpdated Aug 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 0.66×, lower than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 0.66Industry median: 5.64Industry P5: 1.06Peers compared: 261
Price-to-book is 0.58×, lower than 95% of its Biotechnology peers (median 2.97×)Notable
Price-to-book: 0.58Industry median: 2.97Industry P5: 1.03Peers compared: 261
Financial Health
Altman Z-Score 0.21: distress zoneCritical
Altman Z-Score: 0.21
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
IOL Chemicals and Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Cheng Yi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zura Bio Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Lifecome Biochemistry Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Aquestive Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Arvinas Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Eiken Chemical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pharmicell Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Regenxbio Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Tibet Aim Pharm Inc.
Tier 1ProductionApproval-Gated PipelineRule